Baxter BioScience to Expand Global Oncology Footprint with Acquisition of Oncaspa Portfolio for Leukemia

20-May-2015 - Baxter International Inc. announced it has signed a definitive agreement to acquire the Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A. The acquisition further accelerates the innovation capabilities and the commercial presence of Baxter BioScience in growing oncology ...

Jerini expands collaboration with Baxter to develop non-intraveneous hemophilia therapy

07-Feb-2007 - Jerini AG announced the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the treatment of hemophilia. The companies have initiated two additional programs aimed at novel targets, potentially offering new therapeutic developments ...

Kuros starts Phase II clinical trial in bone regeneration

Kuros reaches key milestone in its collaboration with Baxter

06-Feb-2007 - Kuros, a biotechnology company that develops novel biologics and biomaterials for localised therapy, announced that it has started a Phase II clinical trial in tibial plateau fractures as part of its collaboration with Baxter in hard and soft tissue repair. The Phase II clinical trial will be ...

BioVeris Completes Additional Vaccine License

New License Adds Neisseria meningitidis group Y and Haemophilus influenzae type b to Bioveris's Vaccine Candidate Portfolio

29-Jan-2007 - BioVeris Corporation announced that it has entered into a new Technology License Agreement with Baxter Healthcare Corporation. BioVeris received an exclusive, worldwide license to certain patent rights and know-how to use Neisseria meningitidis group Y and Haemophilus influenzae type b (Hib) ...

Lipoxen Announces $75M Agreement with Baxter to Develop New Blood Clotting Factors

18-Dec-2006 - Lipoxen PLC announced that the company has entered into an exclusive worldwide development and licence agreement with a subsidiary of Baxter International Inc. to develop improved, longer-acting forms of blood-clotting factors. The signing of this agreement by Baxter triggers a $1 million payment ...

GenOdyssee SA Announces Research Partnership with Baxter AG

25-Oct-2006 - GenOdyssee S.A., a biotechnology company dedicated to the discovery of novel protein therapeutic products, has entered into a research and development cooperation agreement with Baxter AG. GenOdyssee will use its unique intellectual property position in the field of protein therapeutics, as well ...

Cerus Obtains Exclusive Rights to INTERCEPT Blood System from Baxter

15-Feb-2006 - Cerus Corporation and subsidiaries of Baxter International Inc. announced that they have entered into a definitive agreement for Cerus to obtain Baxter¡¦s remaining commercial rights to the INTERCEPT· Blood System for platelets and plasma effective February 1, 2006. Cerus now has exclusive ...

Acambis announces significant progress on its MVA smallpox vaccine programme with publication of Phase I trial results

30-Jun-2005 - Acambis plc announced an update on its programme to develop and manufacture its Modified Vaccinia Ankara ("MVA') attenuated smallpox vaccine, MVA3000, with results from a Phase I clinical trial of MVA3000. Acambis is co-developing the MVA3000 vaccine with Baxter Healthcare SA ("Baxter'), which is ...

Baxter and Miltenyi Biotec Sign 5-Year Distribution Agreement for Cellular Therapy Products

01-Oct-2003 - Baxter Healthcare Corporation and Miltenyi Biotec GmbH announced today that they have signed an agreement whereby Miltenyi Biotec will have exclusive rights for five years to distribute, market and sell Baxter's cellular therapy products worldwide, with the exception of China, Japan, Korea and ...

Baxter and Cerus Halt Red Blood Cell Clinical Trials for Investigational Pathogen Inactivation System

05-Sep-2003 - Cerus Corporation and subsidiaries of Baxter International Inc. announced they are voluntarily halting Phase III trials for their pathogen-inactivated red blood cell program. The companies made this decision as a precautionary measure after two study patients developed antibodies to red blood ...